Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887647502> ?p ?o ?g. }
- W2887647502 endingPage "2742" @default.
- W2887647502 startingPage "2729" @default.
- W2887647502 abstract "Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial-mesenchymal transition and acts synergistically with 5-fluorouracil Toru Kurata, Sachio Fushida, Jun Kinoshita, Katsunobu Oyama, Takahisa Yamaguchi, Mitsuyoshi Okazaki, Tomoharu Miyashita, Hidehiro Tajima, Itasu Ninomiya, Tetsuo Ohta Department of Gastroenterological Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan Background: Characterized by aggressive proliferation, extensive stromal fibrosis, and resulting drug resistance, peritoneal dissemination in gastric cancer remains associated with poor prognosis. Interaction between cancer and stromal cells accelerates tumor progression via epithelial–mesenchymal transition (EMT), which is one of the major causes of tissue fibrosis, and human peritoneal mesothelial cells (HPMCs) play important roles as cancer stroma in peritoneal dissemination. Transforming growth factor-β (TGF-β) has a pivotal function in the progression of EMT, and Smad proteins play an important role in the TGF-β signaling pathway. Eribulin mesylate (eribulin), a nontaxane microtubule dynamics inhibitor used for the treatment of advanced breast cancer, inhibits EMT changes in triple-negative breast cancer cells. We examined its ability to inhibit tumor progression and EMT changes resulting from the interaction between gastric cancer cells and HPMCs and to act synergistically with 5-fluorouracil (5-FU), a key drug for gastric cancer. Materials and methods: Proliferation of gastric cancer cells and HPMCs isolated from healthy omentum was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Following gastric cancer cell/HPMC coculture, EMT markers were detected by immunofluorescence, immunohistochemistry, and Western blotting; invasion assays were performed; and TGF-β and Smad phosphorylation were assessed by Western blotting and enzyme-linked immunosorbent assay. A mouse fibrotic tumor xenograft model was established using gastric cancer cell/HPMC cocultures. The effect of eribulin and/or 5-FU was tested in each case. Results: Eribulin significantly suppressed gastric cancer cell proliferation and EMT changes in MKN-45 gastric cancer cells and HPMCs induced by their interaction in vitro. Eribulin inhibited EMT at much lower concentrations (≥0.5 nM for MKN-45 and ≥0.1 nM for HPMCs) than its half maximal inhibitory concentrations (2.2 nM for MKN-45 and 8.1 nM for HPMCs), and this resulted, at least partly, from the downregulation of TGF-β/Smad signaling. Eribulin administration of ≥0.1 mg/kg suppressed tumor progression (0.1 mg/kg, p=0.02), and fibrosis was inhibited by lower dose (0.05 mg/kg, p=0.008) in the xenograft model. Furthermore, 0.05 mg/kg administration with 5-FU brought about synergistic antitumor effects (p=0.006). Conclusion: Low-dose eribulin combined with 5-FU might be a promising therapy for peritoneal dissemination in gastric cancer. Keywords: peritoneal dissemination, cancer–stromal interaction, human peritoneal mesothelial cell, TGF-β, Smad, synergism" @default.
- W2887647502 created "2018-08-22" @default.
- W2887647502 creator A5011681054 @default.
- W2887647502 creator A5018007136 @default.
- W2887647502 creator A5021109178 @default.
- W2887647502 creator A5024644803 @default.
- W2887647502 creator A5048730959 @default.
- W2887647502 creator A5056226936 @default.
- W2887647502 creator A5061456550 @default.
- W2887647502 creator A5063817865 @default.
- W2887647502 creator A5075738891 @default.
- W2887647502 creator A5081758735 @default.
- W2887647502 date "2018-08-01" @default.
- W2887647502 modified "2023-09-27" @default.
- W2887647502 title "Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil" @default.
- W2887647502 cites W1525764529 @default.
- W2887647502 cites W1742055280 @default.
- W2887647502 cites W1856257838 @default.
- W2887647502 cites W1858568413 @default.
- W2887647502 cites W1959606306 @default.
- W2887647502 cites W1977075884 @default.
- W2887647502 cites W1980212074 @default.
- W2887647502 cites W1981898048 @default.
- W2887647502 cites W1983225377 @default.
- W2887647502 cites W1985968411 @default.
- W2887647502 cites W1986561475 @default.
- W2887647502 cites W1987330052 @default.
- W2887647502 cites W1990488038 @default.
- W2887647502 cites W1993965518 @default.
- W2887647502 cites W2000099153 @default.
- W2887647502 cites W2017385061 @default.
- W2887647502 cites W2018563247 @default.
- W2887647502 cites W2028593825 @default.
- W2887647502 cites W2028726843 @default.
- W2887647502 cites W2033732670 @default.
- W2887647502 cites W2034903741 @default.
- W2887647502 cites W2038569449 @default.
- W2887647502 cites W2048891815 @default.
- W2887647502 cites W2051927047 @default.
- W2887647502 cites W2052744621 @default.
- W2887647502 cites W2054432602 @default.
- W2887647502 cites W2057440670 @default.
- W2887647502 cites W2062809449 @default.
- W2887647502 cites W2063011414 @default.
- W2887647502 cites W2067490860 @default.
- W2887647502 cites W2076583198 @default.
- W2887647502 cites W2077945404 @default.
- W2887647502 cites W2081878240 @default.
- W2887647502 cites W2081938650 @default.
- W2887647502 cites W2082153724 @default.
- W2887647502 cites W2087307986 @default.
- W2887647502 cites W2090907870 @default.
- W2887647502 cites W2098455835 @default.
- W2887647502 cites W2100751052 @default.
- W2887647502 cites W2102782790 @default.
- W2887647502 cites W2103328690 @default.
- W2887647502 cites W2121096799 @default.
- W2887647502 cites W2123851255 @default.
- W2887647502 cites W2127152525 @default.
- W2887647502 cites W2137545466 @default.
- W2887647502 cites W2138941973 @default.
- W2887647502 cites W2143086668 @default.
- W2887647502 cites W2145445766 @default.
- W2887647502 cites W2157576385 @default.
- W2887647502 cites W2160479465 @default.
- W2887647502 cites W2163753908 @default.
- W2887647502 cites W2167938395 @default.
- W2887647502 cites W2171075804 @default.
- W2887647502 cites W2252397189 @default.
- W2887647502 cites W2259955047 @default.
- W2887647502 cites W2304610908 @default.
- W2887647502 cites W2345876088 @default.
- W2887647502 cites W2399354607 @default.
- W2887647502 cites W2620419343 @default.
- W2887647502 cites W2917837889 @default.
- W2887647502 doi "https://doi.org/10.2147/cmar.s167846" @default.
- W2887647502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6101023" @default.
- W2887647502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30147370" @default.
- W2887647502 hasPublicationYear "2018" @default.
- W2887647502 type Work @default.
- W2887647502 sameAs 2887647502 @default.
- W2887647502 citedByCount "13" @default.
- W2887647502 countsByYear W28876475022019 @default.
- W2887647502 countsByYear W28876475022020 @default.
- W2887647502 countsByYear W28876475022021 @default.
- W2887647502 countsByYear W28876475022022 @default.
- W2887647502 countsByYear W28876475022023 @default.
- W2887647502 crossrefType "journal-article" @default.
- W2887647502 hasAuthorship W2887647502A5011681054 @default.
- W2887647502 hasAuthorship W2887647502A5018007136 @default.
- W2887647502 hasAuthorship W2887647502A5021109178 @default.
- W2887647502 hasAuthorship W2887647502A5024644803 @default.
- W2887647502 hasAuthorship W2887647502A5048730959 @default.
- W2887647502 hasAuthorship W2887647502A5056226936 @default.
- W2887647502 hasAuthorship W2887647502A5061456550 @default.
- W2887647502 hasAuthorship W2887647502A5063817865 @default.
- W2887647502 hasAuthorship W2887647502A5075738891 @default.
- W2887647502 hasAuthorship W2887647502A5081758735 @default.